Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Aptorum Group stock
Learn how to easily invest in Aptorum Group stock.
Aptorum Group Limited is a biotechnology business based in the US. Aptorum Group shares (APM) are listed on the NASDAQ and all prices are listed in US Dollars.
How to buy shares in Aptorum Group
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – APM – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Aptorum Group stock price (NASDAQ: APM)Use our graph to track the performance of APM stocks over time.
Aptorum Group shares at a glance
|Latest market close||$1.32|
|52-week range||$1.43 - $4.94|
|50-day moving average||$1.93|
|200-day moving average||$2.52|
|Wall St. target price||$15.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.11|
Buy Aptorum Group shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Aptorum Group stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Aptorum Group price performance over time
|1 week (2022-01-10)||-11.41%|
|1 month (2021-12-17)||-29.03%|
|3 months (2021-10-15)||-49.03%|
|6 months (2021-07-16)||-53.19%|
|1 year (2021-01-15)||-60.12%|
|2 years (2020-01-17)||-90.85%|
|3 years (2019-01-17)||15.18|
|5 years (2017-01-13)||N/A|
Aptorum Group financials
|Revenue TTM||$1.2 million|
|Gross profit TTM||$-103,514|
|Return on assets TTM||-47.48%|
|Return on equity TTM||-23.61%|
|Market capitalisation||$53.1 million|
TTM: trailing 12 months
Aptorum Group share dividends
We're not expecting Aptorum Group to pay a dividend over the next 12 months.
Have Aptorum Group's shares ever split?
Aptorum Group's shares were split on a 3:1 basis on 1 May 2011. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Aptorum Group shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Aptorum Group shares which in turn could have impacted Aptorum Group's share price.
Aptorum Group share price volatility
Over the last 12 months, Aptorum Group's shares have ranged in value from as little as $1.425 up to $4.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptorum Group's is -0.1863. This would suggest that Aptorum Group's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Aptorum Group has bucked the trend.
Aptorum Group overview
Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. .
Aptorum Group in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Aptorum Group (NASDAQ:APM) investors are sitting on a loss of 90% if they invested three years ago
Frequently asked questionsWhat percentage of Aptorum Group is owned by insiders or institutions?
Currently 33.409% of Aptorum Group shares are held by insiders and 3.995% by institutions. When does the fiscal year end for Aptorum Group?
Aptorum Group's fiscal year ends in December. Where is Aptorum Group based?
Aptorum Group's address is: 17 Hanover Square, London, United Kingdom, W1S 1BN What is Aptorum Group's ISIN number?
Aptorum Group's international securities identification number is: KYG6096M1069 What is Aptorum Group's CUSIP number?
Aptorum Group's Committee on Uniform Securities Identification Procedures number is: G6096M106
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
How to buy Specialty Building Products (SBP) stock when it goes public
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
How to buy HeartCore Enterprises (HTCR) stock when it goes public
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.
Ask an Expert